“…Osteosarcoma (OS), which mainly occurs in children and adolescents, is a type of malignant bone tumor characterized by rapid development, a low degree of differentiation, and high metastases. , The 5-year survival rate of OS patients has gained 60–70% owing to progress in diagnosis, surgical protocols, and chemotherapeutic drugs. − Nevertheless, after the development of metastases, the 5-year survival rate sharply decreases to less than 20%. , The gold standard for OS therapy is neoadjuvant chemotherapy, in which patients receive preoperative chemotherapy to reduce the tumor size, surgery to remove the tumor and fill the defects with implants, and postoperative chemotherapy to prevent recurrence. − However, chemotherapy causes many side effects such as a decreased number of blood cells, damage to the immune system, and, most important, inhibition of bone regeneration around the prosthesis, which can induce implant failure. Therefore, the design and construction of implants with antitumor properties, which reduce the need for postoperative chemotherapy, and simultaneously, enhanced bone reconstruction, would be of great significance for OS therapy.…”